Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis

Abstract

Sepsis, a condition caused by severe infections, affects more than 30 million people worldwide every year and remains the leading cause of death in hospitals1,2. Moreover, antimicrobial resistance has become an additional challenge in the treatment of sepsis3, and thus, alternative therapeutic approaches are urgently needed2,3. Here, we show that adoptive transfer of macrophages containing antimicrobial peptides linked to cathepsin B in the lysosomes (MACs) can be applied for the treatment of multidrug-resistant bacteria-induced sepsis in mice with immunosuppression. The MACs are constructed by transfection of vitamin C lipid nanoparticles that deliver antimicrobial peptide and cathepsin B (AMP-CatB) mRNA. The vitamin C lipid nanoparticles allow the specific accumulation of AMP-CatB in macrophage lysosomes, which is the key location for bactericidal activities. Our results demonstrate that adoptive MAC transfer leads to the elimination of multidrug-resistant bacteria, including Staphylococcus aureus and Escherichia coli, leading to the complete recovery of immunocompromised septic mice. Our work provides an alternative strategy for overcoming multidrug-resistant bacteria-induced sepsis and opens up possibilities for the development of nanoparticle-enabled cell therapy for infectious diseases.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Schematic illustration of adoptive macrophage transfer and chemical structures of the vitamin-derived lipids.
Fig. 2: Screening, optimization and characterization of VLNPs.
Fig. 3: Therapeutic effects of MAC-RAWs in MDRSA-induced sepsis mice with immunosuppression.
Fig. 4: Therapeutic effects of MAC-BMDMs in sepsis mice induced with mixed MDR bacteria (Staphylococcus aureus and E. coli) with immunosuppression.

Data availability

The data that support the plots within this paper and other findings of this study are available from the corresponding author upon reasonable request.

Change history

  • 28 April 2020

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

References

  1. 1.

    Reinhart, K. et al. Recognizing sepsis as a global health priority—a WHO resolution. N. Engl. J. Med. 377, 414–417 (2017).

  2. 2.

    van der Poll, T. Immunotherapy of sepsis. Lancet Infect. Dis. 1, 165–174 (2001).

  3. 3.

    Huttunen, R. & Aittoniemi, J. New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis. J. Infect. 63, 407–419 (2011).

  4. 4.

    Hotchkiss, R. S. & Karl, I. E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 138–150 (2003).

  5. 5.

    Otto, G. P. et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit. Care 15, R183 (2011).

  6. 6.

    Hotchkiss, R. S., Monneret, G. & Payen, D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect. Dis. 13, 260–268 (2013).

  7. 7.

    Czermak, B. J. et al. Protective effects of C5a blockade in sepsis. Nat. Med. 5, 788–792 (1999).

  8. 8.

    Ward, P. A. & Fattahi, F. New strategies for treatment of infectious sepsis. J. Leukoc. Biol. 106, 187–192 (2019).

  9. 9.

    Huang, X. et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc. Natl Acad. Sci. USA 106, 6303–6308 (2009).

  10. 10.

    Docke, W. D. et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 3, 678–681 (1997).

  11. 11.

    Presneill, J. J., Harris, T., Stewart, A. G., Cade, J. F. & Wilson, J. W. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am. J. Respir. Crit. Care Med. 166, 138–143 (2002).

  12. 12.

    Galbraith, N., Walker, S., Galandiuk, S., Gardner, S. & Polk, H. C. Jr The significance and challenges of monocyte impairment: for the ill patient and the surgeon. Surg. Infect. 17, 303–312 (2016).

  13. 13.

    Bo, L., Wang, F., Zhu, J., Li, J. & Deng, X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit. Care 15, R58 (2011).

  14. 14.

    Foster, T. J. Immune evasion by staphylococci. Nat. Rev. Microbiol. 3, 948–958 (2005).

  15. 15.

    Garzoni, C. & Kelley, W. L. Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol. 17, 59–65 (2009).

  16. 16.

    Lewis, A. J., Richards, A. C. & Mulvey, M. A. Invasion of host cells and tissues by uropathogenic bacteria. Microbiol. Spectr. 4, UTI-0026-2016 (2016).

  17. 17.

    Pauwels, A. M., Trost, M., Beyaert, R. & Hoffmann, E. Patterns, receptors, and signals: regulation of phagosome maturation. Trends Immunol. 38, 407–422 (2017).

  18. 18.

    Giles, F. J., Redman, R., Yazji, S. & Bellm, L. Iseganan HCl: a novel antimicrobial agent. Expert Opin. Investig. Drugs 11, 1161–1170 (2002).

  19. 19.

    Linke, M., Herzog, V. & Brix, K. Trafficking of lysosomal cathepsin B-green fluorescent protein to the surface of thyroid epithelial cells involves the endosomal/lysosomal compartment. J. Cell Sci. 115, 4877–4889 (2002).

  20. 20.

    Vasey, P. A. et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents–drug-polymer conjugates. Clin. Cancer Res. 5, 83–94 (1999).

  21. 21.

    Frimodt-Møller, N., Knudsen, J. & Espersen, F. in Handbook of Animal Models of Infection 127–136 (1999).

  22. 22.

    McVicker, G. et al. Clonal expansion during Staphylococcus aureus infection dynamics reveals the effect of antibiotic intervention. PLoS Pathog. 10, e1003959 (2014).

  23. 23.

    Crow, D. Could iPSCs enable “off-the-shelf” cell therapy? Cell 177, 1667–1669 (2019).

  24. 24.

    Ying, W., Cheruku, P. S., Bazer, F. W., Safe, S. H. & Zhou, B. Investigation of macrophage polarization using bone marrow derived macrophages. J. Vis. Exp. 76, e50323 (2013).

  25. 25.

    Zhang, C. et al. Chemotherapy drugs derived nanoparticles encapsulating mRNA encoding tumor suppressor proteins to treat triple-negative breast cancer. Nano Res. 12, 855–861 (2019).

  26. 26.

    Li, B. et al. An orthogonal array optimization of lipid-like nanoparticles for mRNA delivery in vivo. Nano Lett. 15, 8099–8107 (2015).

  27. 27.

    Su, X., Fricke, J., Kavanagh, D. G. & Irvine, D. J. In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. Mol. Pharm. 8, 774–787 (2011).

  28. 28.

    Zhang, L. et al. High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. Proc. Natl Acad. Sci. USA 104, 4606–4611 (2007).

Download references

Acknowledgements

We acknowledge the use of the core facility provided by the Campus Microscopy & Imaging Facility at Ohio State University. X.Z. acknowledges support from Fundamental Research Funds for the Central Universities (No. DUT18RC(3)027). Y.D. acknowledges support from National Institutes of Health (NIH) through the Maximizing Investigators’ Research Award R35GM119679 of the National Institute of General Medical Sciences as well as the start-up fund from the College of Pharmacy at Ohio State University.

Author information

Affiliations

Authors

Contributions

X.H. and X.Z. conceived and designed the experiments. X.H. and X.Z. performed the experiments and wrote the paper. W.Z. contributed to animal and live-cell imaging. C. Zeng prepared the mRNA. B.D. and D.W.M. contributed to the Cryo-TEM imaging. S.D. and W.L. contributed to the animal experiments. C. Zhang contributed to flow cytometry assays. Y.D. conceived and supervised the project and wrote the paper. The final manuscript was edited and approved by all authors.

Corresponding author

Correspondence to Yizhou Dong.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Peer review information Nature Nanotechnology thanks Timothy Foster, Anthony Gordon and Liangfang Zhang for their contribution to the peer review of this work.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary information

Supplementary Figures 1–10 and RNA sequences.

Reporting Summary

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hou, X., Zhang, X., Zhao, W. et al. Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. Nat. Nanotechnol. 15, 41–46 (2020). https://doi.org/10.1038/s41565-019-0600-1

Download citation

Further reading

  • Addressing Nanomaterial Immunosafety by Evaluating Innate Immunity across Living Species

    • Diana Boraschi
    • , Andi Alijagic
    • , Manon Auguste
    • , Francesco Barbero
    • , Eleonora Ferrari
    • , Szabolcs Hernadi
    • , Craig Mayall
    • , Sara Michelini
    • , Natividad I. Navarro Pacheco
    • , Alessandra Prinelli
    • , Elmer Swart
    • , Benjamin J. Swartzwelter
    • , Neus G. Bastús
    • , Laura Canesi
    • , Damjana Drobne
    • , Albert Duschl
    • , Marie‐Ann Ewart
    • , Jutta Horejs‐Hoeck
    • , Paola Italiani
    • , Birgit Kemmerling
    • , Peter Kille
    • , Petra Prochazkova
    • , Victor F. Puntes
    • , David J. Spurgeon
    • , Claus Svendsen
    • , Colin J. Wilde
    •  & Annalisa Pinsino

    Small (2020)